BridgeBio Oncology Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
BridgeBio Oncology Therapeutics, Inc. (BBOT) had Debt Securities, Available-for-sale, Amortized Cost of $291.03 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $291.03M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $337.21M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $51.76M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $59.51M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $291.03M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $337.21M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $51.76M POS AM · filed 2026-04-30 |
| 2025-09-30 | $59.51M 10-Q · filed 2025-11-12 |
| 2024-12-31 | $124.43M POS AM · filed 2026-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |